New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
13:08 EDTINSYInsys Therapeutics weakness a buying opportunity, says JMP Securities
JMP Securities said Insys Therapeutics (INSY) is weak on concerns that Subsys may be added to Express Scripts' (ESRX) exclusion list in 2015. The analyst does not know if it will or not be added but said the potential impact would not be material to sales or growth because the product is not included in any PBM preferred formula positions and has prior authorization requirements. The analyst would use weakness as a buying opportunity and reiterates its Outperform rating and $65 price target.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
06:51 EDTINSYInsys Therapeutics enrolls first patient for Phase II study of CBD
Insys Therapeutics announced that the Company has enrolled the first patient in a Phase II clinical study for the treatment of infantile spasms using its pharmaceutical CBD product candidate.
February 1, 2016
08:14 EDTINSYInsys Therapeutics longer term outlook stable, says RBC Capital
After surveying 40 doctors, including nine who prescribed large amounts of Insys' Subsys, RBC Capital says that payor pushback on the drug is "limited," while 95% of all the doctors surveyed and 89% of the high prescribers "intend to write as many or more Subsys prescriptions this year" as last year. The firm thinks the stock's valuation is attractive following its 61% pullback since July. It trimmed its price target on the stock to $44 from $49 but keeps an Outperform rating. .

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use